- Timetable
- Download all abstracts
- Plenary Lectures
- MSSJ Special Program
- Award Lecture
- Symposium Sessions（Day1, Day2）
- Fundamental Sessions（Day1, Day3）
- Young Researchers' Sessions (Int'l)（Day1, Day3）
- Young Researchers' Sessions（Day1, Day3）
- Poster Presentations（Day1, Day2, Day3）
- Evening Workshop
- Corporate Program
Symposium Sessions
Day 2, June 11（Tue.） 10:01-10:23 Room C (Conference Room 201)
- 2C-S-1001
International Survey on Imaging Mass Spectrometry Methods and Applications for Drug Discovery and Development
(1JAIMS, 2IMSS)
oYukari Tanaka1, Eric Solon2, Reid Groseclose2, Stacy Ho2, Kouji Tanaka1, Naoyuki Nakada1, Stefan Linehan2, Masanobu Nishidate1, Hiroyuki Yokoi1, Kenichi Watanabe1, Yoko Urasaki1, Tomomi Ishida1, Hidefumi Kaji1, Rika Komatsu1, Kenji Yoshida1, Hiroshi Yamazaki1, Kosuke Saito1, Yoshiro Saito1
Imaging mass spectrometry (IMS) has emerged as a powerful technology in the pharmaceutical industry with broad potential to enhance the discovery and development of new medicines. As with all new technologies used to support the discovery and development of new pharmaceuticals, scientists must develop, validate, and establish best practices to assure that the integrity of the data obtained supports new drug registration. The Imaging Mass Spectrometry Society (IMSS, leader: Eric Solon) and the Japan Association for Imaging Mass Spectrometry (JAIMS, leader: Yukari Tanaka) are conducting a thorough survey of IMS scientists, data analysts/users, project managers/leaders, and pharmaceutical compliance specialists who are currently using IMS techniques in support of their drug discovery and development efforts and/or who plan to use such tools as best practices are established. We would like to widely deliver new drugs to more patients through appropriate use of IMS technology and drug research and development.